DelveInsight forecasts growth in Adalimumab biosimilars market
DelveInsight has released a report projecting growth in the Adalimumab biosimilars market. The analysis covers over 35 companies and their respective drugs in both marketed and pipeline stages.
DelveInsight, a market research firm, has published a new report indicating an expected rise in the Adalimumab biosimilars market. The report, titled "Adalimumab Biosimilar Insight 2024," offers a comprehensive analysis of the global landscape.
The study details insights into more than 35 companies actively involved in the Adalimumab biosimilars sector, alongside over 35 marketed and pipeline drugs. The analysis encompasses product profiles, clinical and non-clinical stage development, and assessments based on product type, stage, route of administration, and molecule type.
Adalimumab, commonly known by its brand name Humira, is a biologic medication used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and psoriasis. It functions by inhibiting tumor necrosis factor alpha (TNF-α), a protein that triggers inflammation and joint damage.
Key companies mentioned in the report that are developing or marketing Adalimumab biosimilars include BioXpress Therapeutics, ISU Abxis, Zydus Cadila, Alvotech, Celltrion, Sandoz, and Amgen, among others. The report aims to provide a detailed overview of the current Adalimumab biosimilars market and its future trajectory.